The strategic partnership will cover the development and the commercialisation of the product which has already demonstrated efficacy and safety
Nestlé Health Science and Epitomee Medical, a privately held Israel-based bio-medical company developing treatments for the overweight and obese population based on its gastric retention platform, has entered into a strategic partnership for the development and commercialisation of an innovative polymer-based ingestible product aimed at promoting weight loss and improving health.
The strategic partnership will cover the development and the commercialisation of the product which has already demonstrated efficacy and safety in various pre-clinical and clinical studies with significant weight loss reduction and other beneficial health impacts.
Hans-Juergen Woerle, Chief Scientific & Medical Officer of Nestlé Health Science, said: "The research and development that Epitomee is doing is very promising. We look forward to working together to realise the commercialisation of the product, an innovative approach to reducing weight and managing other associated metabolic health co-morbidities"
Dan Hashimshony, CEO of Epitomee added: "Nestlé Health Science is an ideal strategic partner for Epitomee. Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders will be instrumental to Epitomee's worldwide commercialisation success. We are excited about the opportunity that this deal brings to Epitomee and to the many millions of people around the world with obesity and other metabolic issues. This transformational deal is another recognition of the good science, the hard work, commitment and vision of our team."
Under the terms of the agreement, Epitomee grants Nestlé Health Science exclusive and global commercial rights to use the product in the weight loss market, and potentially to address other disorders including prediabetes and Type 2 Diabetes.